Cagrilintide–Semaglutide in Adults with Overweight or Obesity and Type 2 Diabetes
Once-weekly cagrilintide-semaglutide (at a dose of 2.4 mg each) resulted in a significantly lower body weight than placebo in adults with obesity and type 2 diabetes. (Funded by Novo Nordisk; REDEFINE 2 ClinicalTrials.gov number, NCT05394519.).
Authors
- Ildiko Lingvay (ORCID: https://orcid.org/0000-0001-7006-7401)
- Carel Wynand le Roux (ORCID: https://orcid.org/0000-0001-5521-5445)
- Christa Broholm
- Sue D. Pedersen (ORCID: https://orcid.org/0000-0002-4355-1764)
- Julio Rosenstock (ORCID: https://orcid.org/0000-0001-8324-3275)
- Astrid Eliasen (ORCID: https://orcid.org/0000-0002-2261-0323)
- Harpreet S. Bajaj (ORCID: https://orcid.org/0000-0002-1461-1465)
- Melanie Jane Davies (ORCID: https://orcid.org/0000-0002-9987-9371)
- Christian Bøge Lyndgaard (ORCID: https://orcid.org/0000-0001-8246-9002)
- W. Timothy Garvey
Institutions
- University College Dublin (IE)
- University of Leicester (GB)
- Novo Nordisk (Denmark) (DK)
- University of Alabama at Birmingham (US)
- LMC Diabetes & Endocrinology (Canada) (CA)
- Velocity Clinical Research (United States) (US)
- NIHR Leicester Biomedical Research Centre (GB)
- The University of Texas Southwestern Medical Center (US)
Publication Details
- Journal
- New England Journal of Medicine
- Published
- 2025-06-22
- DOI
- https://doi.org/10.1056/nejmoa2502082
- Citations
- 61
- Primary Topic
- Diabetes Treatment and Management
- Type
- article
- Field-Weighted Citation Impact
- 78.99
Funders
- Novo Nordisk